[go: up one dir, main page]

HK1096409B - Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof - Google Patents

Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof Download PDF

Info

Publication number
HK1096409B
HK1096409B HK07101187.4A HK07101187A HK1096409B HK 1096409 B HK1096409 B HK 1096409B HK 07101187 A HK07101187 A HK 07101187A HK 1096409 B HK1096409 B HK 1096409B
Authority
HK
Hong Kong
Prior art keywords
formula
compound
synthesis
group
tert
Prior art date
Application number
HK07101187.4A
Other languages
Chinese (zh)
Other versions
HK1096409A1 (en
Inventor
Thierry Dubuffet
Jean-Pierre Lecouve
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03292131A external-priority patent/EP1380590B1/en
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HK1096409A1 publication Critical patent/HK1096409A1/en
Publication of HK1096409B publication Critical patent/HK1096409B/en

Links

Description

Novel method for the synthesis of perindopril and its pharmaceutically acceptable salts
The present invention relates to a process for the synthesis of perindopril of formula (I) below and pharmaceutically acceptable salts thereof:
perindopril and its pharmaceutically acceptable salts, more specifically its tert-butylamine salt, have important pharmacological properties.
Their main property is to inhibit angiotensin I converting enzyme (or kininase II), so that they are capable of preventing, on the one hand, the conversion of the decapeptide angiotensin I to the octapeptide angiotensin II (a vasoconstrictor) and, on the other hand, their degradation of bradykinin (a vasodilator) to inactive peptides.
Both effects contribute to the beneficial effects of perindopril in cardiovascular diseases, especially arterial hypertension and insufficient blood supply to the heart.
Perindopril, its preparation process and its use in therapy are described in european patent EP 0049658.
In view of the pharmaceutical value of said compounds, it is important to be able to obtain perindopril in high yield and excellent purity using reasonably priced raw materials with a competitive synthesis process that is easy to convert to industrial scale.
Patent EP 0308341 describes the industrial synthesis of perindopril by coupling of benzyl (2S, 3aS, 7aS) -octahydroindole-2-carboxylate with ethyl N- [ (S) -1-carboxybutyl ] - (S) -alanine followed by deprotection of the carboxyl group of the heterocycle using catalytic hydrogenation.
The applicant has now developed a new process for the synthesis of perindopril.
More specifically, the present invention relates to a process for the synthesis of perindopril and its pharmaceutically acceptable salts, characterized in that a compound of formula (II):
in the formula R1Represents a hydrogen atom or a benzyl group or a linear or branched chain (C)1-C6) An alkyl group, with a compound of formula (III) having S configuration:
wherein X represents a halogen atom and R2Represents a protecting group for the amino function, which, after deprotection of the amino function, gives the compound of formula (IV):
in the formula R1As defined above, the compound of formula (IV) is then reacted with a compound of formula (V) below in the presence of a base:
wherein G represents a chlorine, bromine or iodine atom or a p-toluenesulfonyloxy, methanesulfonyloxy or trifluoromethanesulfonyloxy group, to give a compound of the following formula (VI):
in the formula R1As is defined above, the first and second parts,
hydrogenation of the compounds of the formula (VI) in the presence of catalysts, for example palladium, platinum, rhodium or nickel, if necessary after deprotection gives the compounds of the formula (I).
In the process of the invention, mention may be made, as non-limiting examples, of tert-butoxycarbonyl and benzyl groups of amino-functional protecting groups which may be used.
Preferably R1Represents a benzyl group. In this case, the amino-functional group-protecting group is preferably a tert-butoxycarbonyl group.
In the reaction of the compounds of formulae (II) and (III) or of formulae (IV) and (V), as non-limiting examples, the bases which can be used are organic amines, such as triethylamine, pyridine, N-methylmorpholine or diisopropylethylamine, and inorganic bases, such as NaOH, KOH, Na2CO3、K2CO3、NaHCO3Or KHCO3
Example 1: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) -butylamino]-propionyl } -octahydro-1H-indole-2-carboxylic acid tert-butylamine salt
Step A: (2S) -1- { (2S) -2- [ (tert-butoxycarbonyl) -amino]-propionyl } -2, 3, 4, 5, 6, 7-hexahydro-1H-indole-2-carboxylic acid benzyl ester
A reactor was charged with 200g of benzyl (2S) -2, 3, 4, 5, 6, 7-hexahydro-1H-indole-2-carboxylate, 1.5 l of dichloromethane, the temperature of the reaction mixture was then adjusted to 0 ℃ and 107ml of triethylamine were added, followed by 162g of (2S) -2- [ (tert-butoxycarbonyl) -amino ] -propionyl chloride. The mixture was then brought to room temperature. After stirring at this temperature for 1h, the mixture was washed with water and then with a dilute acetic acid solution. The benzyl (2S) -1- { (2S) -2- [ (tert-butoxycarbonyl) -amino ] -propionyl } -2, 3, 4, 5, 6, 7-hexahydro-1H-indole-2-carboxylate solution thus obtained may be used as it is in the subsequent step.
Step B: (2S) -1- { (2S) -2-aminopropionyl } -2, 3, 4, 5, 6, 7-hexahydro-1H-indole-2-carboxylic acid benzyl ester
A reactor was charged with the solution obtained in the previous step, and then 133g of trifluoroacetic acid was added. After stirring at room temperature for 1 hour 30 minutes, the mixture was washed with water and then with a saturated sodium bicarbonate solution, and then the solvent was distilled off to give benzyl (2S) -1- { (2S) -2-aminopropionyl } -2, 3, 4, 5, 6, 7-hexahydro-1H-indole-2-carboxylate.
Step C: (2S) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) -butylamino]-propionyl } -2, 3, 4, 5, 6, 7-hexahydro-1H-indole-2-carboxylic acid benzyl ester
A reactor was charged with 200g of the compound obtained in the previous step, 106ml of diisopropylethylamine and 1.5L of tetrahydrofuran, and then 183g of (2R) -2-p-toluenesulfonyloxy-pentanoic acid ethyl ester was added, followed by heating at 70 ℃ for 2 h. After cooling back to room temperature, the medium is washed with water and then dried. The residue was dissolved in dichloromethane. Hydrochloric acid solution (2M) was added until the pH was about 7.5. After decantation, the solvent is evaporated to give benzyl (2S) -1- (2S) -2- [ (1S) -1- (ethoxycarbonyl) -butylamino ] -propionyl } -2, 3, 4, 5, 6, 7-hexahydro-1H-indole-2-carboxylate.
Step D: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) -butylamino]-propionyl-octahydro-1H-indole-2-carboxylic acid
A hydrogenator was charged with 200g of the compound obtained in the previous step in acetic acid, followed by the addition of 5g of 10% Pt/C. Hydrogenation at a pressure of 5 bar and a temperature of 15-30 ℃ until the theoretical amount of hydrogen is absorbed.
The catalyst was removed by filtration and then cooled to 0-5 ℃ and the resulting solid was collected by filtration. The filter cake was washed and dried until constant weight.
This gave (2S, 3aS, 7aS) -1- (2S) -2- [ (1S) -1- (ethoxycarbonyl) -butylamino ] -propionyl } -octahydro-1H-indole-2-carboxylic acid in a yield of 85% and an enantiomeric purity of 98%.
Step E: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) -butylamino]-propionyl } -octahydro-1H-indole-2-carboxylic acid tert-butylamine salt
The precipitate (200g) from the previous step was dissolved in 2.8 liters of acetonitrile, then 40g of tert-butylamine and 0.4 liters of ethyl acetate were added.
The suspension obtained is then heated to reflux until complete dissolution, and the solution obtained is then filtered while hot and cooled with stirring until the temperature reaches 15-20 ℃. The precipitate was filtered, reslurried in acetonitrile, dried, and recrystallized from ethyl acetate to give the desired product in 95% yield and 99% enantiomeric purity.
Example 2: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) -butylamino]-propionyl } -octahydro-1H-indole-2-carboxylic acid tert-butylamine salt
Steps A and B: same as in steps A and B of example 1
Step C: (2S) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) -butylamino]-propionyl } -2, 3, 4, 5, 6, 7-hexahydro-1H-indole-2-carboxylic acid benzyl ester
A reactor was charged with 200g of the compound obtained in the previous step, 106ml of diisopropylethylamine and 1.5 l of ethyl acetate, followed by addition of 165g of ethyl (2R) -2-chloro-pentanoate and heating at 50 ℃ for 3 h. After cooling to room temperature, the medium is washed with water and dried. The residue was dissolved in dichloromethane. Hydrochloric acid solution (2M) was added to adjust the pH to about 7.5. After decantation, the solvent was evaporated to give benzyl (2S) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) -butylamino ] -propionyl } -2, 3, 4, 5, 6, 7-hexahydro-1H-indole-2-carboxylate.
Steps D and E: same as in steps D and E of example 1.

Claims (9)

1. A process for synthesizing a compound of the formula (I):
characterized in that a compound of formula (II):
in the formula R1Represents a hydrogen atom or a benzyl group or a linear or branched C1-6An alkyl group, with a compound of formula (III) having S configuration:
wherein X represents a halogen atom and R2A protecting group representing an amino function which, after deprotection of the amino function, gives a compound of formula (IV):
in the formula R1As defined above, the compound of formula (IV) is then reacted with a compound of formula (V) below in the presence of a base:
wherein G represents a chlorine, bromine or iodine atom or a p-toluenesulfonyloxy, methanesulfonyloxy or trifluoromethanesulfonyloxy group, to give a compound of the following formula (VI):
in the formula R1As is defined above, the first and second parts,
hydrogenating the compound of formula (VI) in the presence of a catalyst to obtain the compound of formula (I) after deprotection when a protecting group is present, and optionally converting the compound of formula (I) into a pharmaceutically acceptable salt.
2. The synthesis method according to claim 1, characterized in that the catalyst is a palladium, platinum, rhodium or nickel catalyst.
3. The method of claim 1, wherein the amino-functional protecting group is tert-butoxycarbonyl or benzyl.
4. The method of synthesis of claim 3, wherein R is1Represents a benzyl group and the amino functional group protecting group is tert-butoxycarbonyl.
5. Synthesis process according to any one of claims 1 to 4, characterized in that the base used for the reaction of the compounds of formula (II) with (III) is an organic amine selected from triethylamine, pyridine, N-methylmorpholine and diisopropylethylamine, or an inorganic base.
6. The synthesis method according to claim 5, characterized in that the inorganic base is NaOH, KOH, Na2CO3、K2CO3、NaHCO3Or KHCO3
7. Synthesis process according to any one of claims 1 to 4, characterized in that the base used for the reaction of the compound of formula (IV) with (V) is an organic amine selected from triethylamine, pyridine, N-methylmorpholine and diisopropylethylamine, or an inorganic base.
8. The synthesis method according to claim 7, characterized in that the inorganic base is NaOH, KOH, Na2CO3、K2CO3、NaHCO3Or KHCO3
9. A synthesis process according to any one of claims 1-4, wherein perindopril is in the form of the tert-butylamine salt.
HK07101187.4A 2003-08-29 2004-08-27 Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof HK1096409B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03292131.4 2003-08-29
EP03292131A EP1380590B1 (en) 2003-08-29 2003-08-29 Method for synthesis of perindopril and its pharmaceutically acceptable salts
PCT/FR2004/002196 WO2005023841A1 (en) 2003-08-29 2004-08-27 Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof

Publications (2)

Publication Number Publication Date
HK1096409A1 HK1096409A1 (en) 2007-06-01
HK1096409B true HK1096409B (en) 2009-01-23

Family

ID=

Similar Documents

Publication Publication Date Title
JP4377412B2 (en) Method for synthesizing perindopril and pharmaceutical salts thereof
JP4347341B2 (en) Novel synthesis of perindopril and pharmaceutically acceptable salts thereof
JP4347342B2 (en) Novel synthesis of perindopril and pharmaceutically acceptable salts thereof
CN100395264C (en) Novel method for the synthesis of perindopril and its pharmaceutically acceptable salts
JP4331207B2 (en) Novel synthesis method of perindopril and pharmaceutically acceptable salts thereof
ES2240919T3 (en) NEW PROCEDURE FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
JP4331206B2 (en) Novel synthesis method of perindopril and pharmaceutically acceptable salts thereof
CN1331883C (en) Method for synthesis of (2s,3as,7as)-1-((s)-alanyl)-octahydro-1h-indole-2-carboxylic acid derivatives and use in the synthesis of perindopril
JP4563372B2 (en) Novel method for synthesizing perindopril and pharmacologically acceptable salts thereof
HK1096409B (en) Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof
JP4263744B2 (en) Novel method for synthesizing perindopril and pharmaceutically acceptable salts thereof
HK1097852B (en) Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof
MXPA06001243A (en) Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof.
HK1096408B (en) Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof
HK1096407B (en) Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof
HK1096689B (en) New process for the synthesis of perindopril and pharmaceutically-acceptable salts thereof
HK1096406B (en) Novel method for the synthesis of perindopril and the pharmaceutiucally acceptable salts thereof
HK1089187B (en) Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof
HK1089188B (en) Novel method of synthesising perindopril and the pharmaceutically-acceptable salts thereof